US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
US5260299A
(en)
*
|
1992-03-05 |
1993-11-09 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
US5256790A
(en)
*
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
USRE40596E1
(en)
*
|
1993-04-08 |
2008-12-02 |
Novartis Ag |
Rapamycin assay
|
GB9307491D0
(en)
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
AU6711994A
(en)
*
|
1993-04-23 |
1994-11-21 |
American Home Products Corporation |
Rapamycin conjugates and antibodies
|
WO1994025022A1
(en)
|
1993-04-23 |
1994-11-10 |
Abbott Laboratories |
Rapamycin conjugates and antibodies
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
US7279561B1
(en)
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
JP4105761B2
(ja)
*
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
US5362718A
(en)
*
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
US6124453A
(en)
*
|
1995-07-04 |
2000-09-26 |
Novartis Ag |
Macrolides
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US6709873B1
(en)
|
1997-04-09 |
2004-03-23 |
Isodiagnostika Inc. |
Method for production of antibodies to specific sites of rapamycin
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
US6511986B2
(en)
|
2000-08-11 |
2003-01-28 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
WO2002024706A2
(en)
|
2000-09-19 |
2002-03-28 |
Wyeth |
Water soluble rapamycin esters
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US20030220297A1
(en)
|
2002-02-01 |
2003-11-27 |
Berstein David L. |
Phosphorus-containing compounds and uses thereof
|
MXPA05001013A
(es)
*
|
2002-07-30 |
2005-05-16 |
Wyeth Corp |
Formulaciones parentales que contienen un hidroxiester de rapamicina.
|
WO2004022124A1
(en)
|
2002-09-06 |
2004-03-18 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
CN102144961A
(zh)
*
|
2003-09-18 |
2011-08-10 |
参天制药株式会社 |
经巩膜递送
|
US7349971B2
(en)
*
|
2004-02-05 |
2008-03-25 |
Scenera Technologies, Llc |
System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
ATE534424T1
(de)
*
|
2004-03-19 |
2011-12-15 |
Abbott Lab |
Mehrfache arzneiabgabe aus einem ballon und eine prothese
|
EP1735321B1
(en)
*
|
2004-04-14 |
2008-10-08 |
Wyeth |
Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
|
BRPI0510277A
(pt)
*
|
2004-04-27 |
2007-10-30 |
Wyeth Corp |
método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
AU2005294382A1
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
CN101048152A
(zh)
*
|
2004-10-28 |
2007-10-03 |
惠氏公司 |
mTOR抑制剂在治疗子宫平滑肌瘤中的应用
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
WO2006086750A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Macusight, Inc. |
Liquid formulations for treatment of diseases or conditions
|
GB0503936D0
(en)
*
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
WO2006102378A2
(en)
*
|
2005-03-21 |
2006-09-28 |
Macusight, Inc. |
Drug delivery systems for treatment of diseases or conditions
|
WO2007032777A2
(en)
|
2005-03-23 |
2007-03-22 |
Abbott Laboratories |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
EP2327429B1
(en)
|
2005-03-23 |
2014-09-17 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
SI2298815T1
(sl)
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
BRPI0618042A2
(pt)
|
2005-11-04 |
2011-08-16 |
Wyeth Corp |
usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
|
US7700614B2
(en)
*
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
JP5528708B2
(ja)
|
2006-02-09 |
2014-06-25 |
参天製薬株式会社 |
安定な製剤ならびにそれらを調製および使用する方法
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
US7678901B2
(en)
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US8222271B2
(en)
|
2006-03-23 |
2012-07-17 |
Santen Pharmaceutical Co., Ltd. |
Formulations and methods for vascular permeability-related diseases or conditions
|
US7883855B2
(en)
*
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
US20080175887A1
(en)
|
2006-11-20 |
2008-07-24 |
Lixiao Wang |
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8430055B2
(en)
*
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
JP2008305262A
(ja)
*
|
2007-06-08 |
2008-12-18 |
Konica Minolta Business Technologies Inc |
サーバ及びシンクライアント環境でのプリンタ紹介方法
|
CN101990439A
(zh)
*
|
2007-07-06 |
2011-03-23 |
特鲁比昂药品公司 |
具有置于c末端的特异性结合结构域的结合肽
|
ES2559311T3
(es)
|
2007-12-19 |
2016-02-11 |
Abbott Laboratories |
Reactivo de extracción de fármacos inmunosupresores para inmunoanálisis
|
US8685995B2
(en)
*
|
2008-03-21 |
2014-04-01 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
MX340204B
(es)
*
|
2008-04-11 |
2016-06-30 |
Emergent Product Dev Seattle |
Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
|
CN104042612A
(zh)
|
2008-11-11 |
2014-09-17 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
CA2761389A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
AU2010313152A1
(en)
|
2009-10-30 |
2012-04-19 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for treating cancer
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US10391059B2
(en)
|
2009-11-11 |
2019-08-27 |
Rapamycin Holdings, Inc. |
Oral rapamycin nanoparticle preparations and use
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
JP2013521002A
(ja)
|
2010-03-05 |
2013-06-10 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
誘導樹状細胞組成物及びその使用
|
MX342590B
(es)
|
2010-04-27 |
2016-10-05 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
|
AU2012229236B2
(en)
|
2011-03-11 |
2017-05-18 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-CD40 antibodies and uses thereof
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
EP2906214A1
(en)
|
2012-10-12 |
2015-08-19 |
The Board of Regents of The University of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
WO2014068070A1
(en)
|
2012-10-31 |
2014-05-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
AU2014236135A1
(en)
|
2013-03-14 |
2015-09-10 |
Thomas Jefferson University |
Androgen receptor down-regulating agents and uses thereof
|
US9808472B2
(en)
|
2013-08-12 |
2017-11-07 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
CA2943609A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
CA2968049A1
(en)
|
2014-04-16 |
2015-10-22 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
AU2015270925A1
(en)
|
2014-06-02 |
2016-12-22 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
CA2960992A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
Mtorc1 inhibitors
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
EP3906943A1
(en)
|
2015-09-04 |
2021-11-10 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
CA2972296A1
(en)
|
2016-06-30 |
2017-12-30 |
Durect Corporation |
Depot formulations
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
EA201990127A1
(ru)
|
2016-12-30 |
2020-08-18 |
Дьюрект Корпорейшн |
Депо-препарат
|
US20210154372A1
(en)
|
2017-05-15 |
2021-05-27 |
C.R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
CN108948046B
(zh)
*
|
2017-05-20 |
2020-11-10 |
鲁南制药集团股份有限公司 |
一种替西罗莫司的中间体及其制备方法
|
US20200129486A1
(en)
|
2017-06-26 |
2020-04-30 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
EP3652306A1
(en)
|
2017-07-13 |
2020-05-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
|
CA3098698A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
US20190336609A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
|
CA3107352A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
CN113164563A
(zh)
|
2018-07-23 |
2021-07-23 |
因柯利尔疗法公司 |
神经性病症的治疗方法
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
JP7262581B2
(ja)
|
2018-11-14 |
2023-04-21 |
ルトニックス,インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
CN113939324A
(zh)
|
2019-04-08 |
2022-01-14 |
巴德外周血管股份有限公司 |
在经改性装置表面上具有药物洗脱涂层的医疗装置
|
JP2022526671A
(ja)
|
2019-04-11 |
2022-05-25 |
エンクリアー セラピーズ, インク. |
脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|